1026TiP A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
Mehmet Altan(The University of Texas MD Anderson Cancer Center), Assuntina G. Sacco(University of California San Diego), Minal Barve(Mary Crowley Cancer Research Center), Z. Lee(Nektar Therapeutics (United States)), Sunil Sharma(Translational Genomics Research Institute), Lara Dunn(Memorial Sloan Kettering Cancer Center), Mario Q. Marcondes(Nektar Therapeutics (United States)), Brian L. Kotzin(Howard Hughes Medical Institute), Ari J. Rosenberg(University of Chicago), Amita Patnaik(South Texas Accelerated Research Therapeutics), Mary Tagliaferri(Nektar Therapeutics (United States)), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Patrick Cobb(St. Vincent's HealthCare), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 0
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
|JAMA|2016|1.1k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816